Abstract:The misfolding and aggregation of α-synuclein is the general hallmark of a group of devastating neurodegenerative pathologies referred to as synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. In such conditions, a range of different misfolded aggregates, including oligomers, protofibrils, and fibrils, are present both in neurons and glial cells. Growing experimental evidence supports the proposition that soluble oligomeric assemblies, formed during the early… Show more
“…The presence of neurons displaying the enrichment of acetylated α-Tubulin in cell bodies and lacking mature LBs inside them, let us to hypothesize that the observed change in acetylated α-Tubulin could be involved in the initial step of α-Synuclein aggregation. We therefore focused on α-Synuclein oligomers 66 , the earliest α-Synuclein aggregated species 36 , 67 , 68 . Using super-resolution microscopy, we found a staging-like distribution between α-Synuclein and acetylated α-Tubulin.…”
Highly specialized microtubules in neurons are crucial to both health and disease of the nervous system, and their properties are strictly regulated by different post-translational modifications, including α-Tubulin acetylation. An imbalance in the levels of acetylated α-Tubulin has been reported in experimental models of Parkinson’s disease (PD) whereas pharmacological or genetic modulation that leads to increased acetylated α-Tubulin successfully rescues axonal transport defects and inhibits α-Synuclein aggregation. However, the role of acetylation of α-Tubulin in the human nervous system is largely unknown as most studies are based on in vitro evidence. To capture the complexity of the pathological processes in vivo, we analysed post-mortem human brain of PD patients and control subjects. In the brain of PD patients at Braak stage 6, we found a redistribution of acetylated α-Tubulin, which accumulates in the neuronal cell bodies in subcortical structures but not in the cerebral cortex, and decreases in the axonal compartment, both in putamen bundles of fibres and in sudomotor fibres. High-resolution and 3D reconstruction analysis linked acetylated α-Tubulin redistribution to α-Synuclein oligomerization and to phosphorylated Ser 129 α-Synuclein, leading us to propose a model for Lewy body (LB) formation. Finally, in post-mortem human brain, we observed threadlike structures, resembling tunnelling nanotubes that contain α-Synuclein oligomers and are associated with acetylated α-Tubulin enriched neurons. In conclusion, we support the role of acetylated α-Tubulin in PD pathogenesis and LB formation.
“…The presence of neurons displaying the enrichment of acetylated α-Tubulin in cell bodies and lacking mature LBs inside them, let us to hypothesize that the observed change in acetylated α-Tubulin could be involved in the initial step of α-Synuclein aggregation. We therefore focused on α-Synuclein oligomers 66 , the earliest α-Synuclein aggregated species 36 , 67 , 68 . Using super-resolution microscopy, we found a staging-like distribution between α-Synuclein and acetylated α-Tubulin.…”
Highly specialized microtubules in neurons are crucial to both health and disease of the nervous system, and their properties are strictly regulated by different post-translational modifications, including α-Tubulin acetylation. An imbalance in the levels of acetylated α-Tubulin has been reported in experimental models of Parkinson’s disease (PD) whereas pharmacological or genetic modulation that leads to increased acetylated α-Tubulin successfully rescues axonal transport defects and inhibits α-Synuclein aggregation. However, the role of acetylation of α-Tubulin in the human nervous system is largely unknown as most studies are based on in vitro evidence. To capture the complexity of the pathological processes in vivo, we analysed post-mortem human brain of PD patients and control subjects. In the brain of PD patients at Braak stage 6, we found a redistribution of acetylated α-Tubulin, which accumulates in the neuronal cell bodies in subcortical structures but not in the cerebral cortex, and decreases in the axonal compartment, both in putamen bundles of fibres and in sudomotor fibres. High-resolution and 3D reconstruction analysis linked acetylated α-Tubulin redistribution to α-Synuclein oligomerization and to phosphorylated Ser 129 α-Synuclein, leading us to propose a model for Lewy body (LB) formation. Finally, in post-mortem human brain, we observed threadlike structures, resembling tunnelling nanotubes that contain α-Synuclein oligomers and are associated with acetylated α-Tubulin enriched neurons. In conclusion, we support the role of acetylated α-Tubulin in PD pathogenesis and LB formation.
“…Alpha-synuclein oligomers induce synaptic impairment, endoplasmic reticulum stress, mitochondrial dysfunction, loss of regulation of proteostasis, neuroinflammation, cell apoptosis, lysosomal dysfunction, oxidative stress, and autophagy impairment [ 27 , 44 , 45 , 46 , 47 , 48 ]. However, the propagative nature of alpha-synuclein [ 49 ] will imply rapid neurodegeneration of the nigrostriatal system when neurotoxic oligomers are formed, which is the opposite of what occurs in the disease. Mutations in the alpha-synuclein gene induce the formation of neurotoxic alpha-synuclein oligomers in familial Parkinson’s disease that are transmitted to neighboring neurons through exosomes [ 49 , 50 , 51 , 52 ].…”
Section: Parkinson’s Diseasementioning
confidence: 99%
“…However, the propagative nature of alpha-synuclein [ 49 ] will imply rapid neurodegeneration of the nigrostriatal system when neurotoxic oligomers are formed, which is the opposite of what occurs in the disease. Mutations in the alpha-synuclein gene induce the formation of neurotoxic alpha-synuclein oligomers in familial Parkinson’s disease that are transmitted to neighboring neurons through exosomes [ 49 , 50 , 51 , 52 ]. Alpha-synuclein alone does not aggregate into neurotoxic oligomers and the question is what induces the aggregation of alpha-synuclein to neurotoxic oligomers in neuromelanin-containing dopaminergic neurons in the nigrostriatal system in idiopathic Parkinson’s disease.…”
One of the biggest problems in the treatment of idiopathic Parkinson’s disease is the lack of new drugs that slow its progression. L-Dopa remains the star drug in the treatment of this disease, although it induces severe side effects. The failure of clinical studies with new drugs depends on the use of preclinical models based on neurotoxins that do not represent what happens in the disease since they induce rapid and expansive neurodegeneration. We have recently proposed a single-neuron degeneration model for idiopathic Parkinson’s disease that requires years to accumulate enough lost neurons for the onset of motor symptoms. This single-neuron degeneration model is based on the excessive formation of aminochrome during neuromelanin synthesis that surpass the neuroprotective action of the enzymes DT-diaphorase and glutathione transferase M2-2, which prevent the neurotoxic effects of aminochrome. Although the neurotoxic effects of aminochrome do not have an expansive effect, a stereotaxic injection of this endogenous neurotoxin cannot be used to generate a preclinical model in an animal. Therefore, the aim of this review is to evaluate the strategies for pharmacologically increasing the expression of DT diaphorase and GSTM2-2 and molecules that induce the expression of vesicular monoamine transporter 2, such as pramipexole.
“…They emphasized the proposition that oligomeric species have more inherent abilities to promptly induce cellular dysfunction and neurotoxicity, while fibrillar conformers are more effective in spreading from neuron to neuron, thus propagating neurodegeneration, as depicted in Figure 1, "cellular mechanisms of neurotoxicity". These conclusions arise from experimental evidences by several researchers, including ourselves, on the prominent neurotoxic potential of oligomeric species, which are not only formed during αS aggregation, but are also released by mature fibrils upon their interaction with the neuronal membrane [4][5][6][7]. The review by Gracia et al presents the state-of-the-art knowledge on αS aggregation and toxicity, which is extremely useful for hypothesizing therapeutic drugs and diagnostic tools for accurate diagnoses.…”
The aberrant aggregation of specific peptides and proteins is the common feature of a range of more than 50 human pathologies, collectively referred to as protein misfolding diseases [...]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.